$ALDX
Aldeyra Therapeutics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517170649 Filed on May 15, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.480M $1.730M $1.460M
YoY Change 1.37% 18.49% 50.52%
% of Gross Profit
Research & Development $3.849M $3.369M $3.511M
YoY Change 35.79% -4.06% 208.99%
% of Gross Profit
Depreciation & Amortization $10.00K $9.660K $8.102K
YoY Change 0.0% 19.23% 547.12%
% of Gross Profit
Operating Expenses $3.849M $3.369M $3.511M
YoY Change 35.79% -4.06% 208.99%
Operating Profit -$5.331M -$5.096M -$4.967M
YoY Change 24.06% 2.59% 135.57%
Interest Expense $26.46K $26.84K $25.04K
YoY Change -4.87% 7.2% -10.67%
% of Operating Profit
Other Income/Expense, Net $21.92K $4.780K -$316.00
YoY Change -473.7% -1612.66% -98.87%
Pretax Income -$5.310M -$5.090M -$4.970M
YoY Change 23.2% 2.41% 132.24%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.309M -$5.091M -$4.967M
YoY Change 23.38% 2.49% 132.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$350.7K -$368.8K -$0.51
COMMON SHARES
Basic Shares Outstanding 15.13M shares 15.13M shares 9.713M shares
Diluted Shares Outstanding 9.713M shares

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.80M $31.20M $23.00M
YoY Change -20.62% 35.65% 46.5%
Cash & Equivalents $14.61M $12.02M $14.65M
Short-Term Investments $11.20M $11.90M $12.90M
Other Short-Term Assets $500.0K $300.0K $300.0K
YoY Change 66.67% 0.0% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.34M $31.47M $23.31M
YoY Change -19.71% 35.02% 46.62%
LONG-TERM ASSETS
Property, Plant & Equipment $47.98K $58.28K $81.47K
YoY Change -36.05% -28.46% 518.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $0.00
YoY Change
Total Long-Term Assets $125.9K $58.28K $127.5K
YoY Change 67.84% -54.27% 284.1%
TOTAL ASSETS
Total Short-Term Assets $26.34M $31.47M $23.31M
Total Long-Term Assets $125.9K $58.28K $127.5K
Total Assets $26.47M $31.53M $23.44M
YoY Change -19.51% 34.54% 47.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $762.7K $694.9K $578.0K
YoY Change -7.36% 20.23% 42.32%
Accrued Expenses $1.039M $1.520M $1.036M
YoY Change -4.21% 46.77% 137.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $310.2K $193.9K $193.9K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $2.112M $2.409M $1.808M
YoY Change -11.02% 33.26% 74.47%
LONG-TERM LIABILITIES
Long-Term Debt $1.016M $1.128M $1.102M
YoY Change 2.39% 2.32% 3.13%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.016M $1.128M $1.102M
YoY Change 2.39% 2.32% 3.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.112M $2.409M $1.808M
Total Long-Term Liabilities $1.016M $1.128M $1.102M
Total Liabilities $3.128M $3.537M $2.910M
YoY Change -7.06% 21.54% 38.25%
SHAREHOLDERS EQUITY
Retained Earnings -$87.70M -$82.39M -$63.57M
YoY Change 29.22% 29.61% 30.67%
Common Stock $111.0M $110.4M $84.09M
YoY Change 14.03% 31.27% 1220429.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.34M $28.00M $24.88M
YoY Change
Total Liabilities & Shareholders Equity $26.47M $31.53M $23.44M
YoY Change -19.51% 34.54% 47.11%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$5.309M -$5.091M -$4.967M
YoY Change 23.38% 2.49% 132.49%
Depreciation, Depletion And Amortization $10.00K $9.660K $8.102K
YoY Change 0.0% 19.23% 547.12%
Cash From Operating Activities -$5.310M -$4.190M -$4.480M
YoY Change 63.38% -6.47% 143.48%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $11.59K $9.234K
YoY Change 25.54% 540.8%
Acquisitions
YoY Change
Other Investing Activities $650.0K $900.0K
YoY Change -130.95%
Cash From Investing Activities $650.0K $890.0K -$10.00K
YoY Change -130.95% -9000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.58M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.00K 10.58M -10.00K
YoY Change -100.23% -105900.0% -100.11%
NET CHANGE
Cash From Operating Activities -5.310M -4.190M -4.480M
Cash From Investing Activities 650.0K 890.0K -10.00K
Cash From Financing Activities -30.00K 10.58M -10.00K
Net Change In Cash -4.690M 7.280M -4.500M
YoY Change -162.87% -261.78% -162.5%
FREE CASH FLOW
Cash From Operating Activities -$5.310M -$4.190M -$4.480M
Capital Expenditures $0.00 $11.59K $9.234K
Free Cash Flow -$5.310M -$4.202M -$4.489M
YoY Change 63.38% -6.41% 143.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
22505756
CY2017Q1 us-gaap Cash
Cash
8706894
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15131880 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10148524
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
377873
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15131880 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15131880 shares
CY2017Q1 us-gaap Assets
Assets
31531617
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q1 us-gaap Assets Current
AssetsCurrent
31473333
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110377077
CY2017Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
11909800
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19302850
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
15132
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
694922
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4747
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
21914547
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1520322
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2017Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1127500
CY2017Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2017Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
193866
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Liabilities
Liabilities
3536610
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31531617
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2409110
CY2017Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
595956
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1857888
CY2017Q1 us-gaap Share Price
SharePrice
5.00
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58284
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.86
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
27995007
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.79
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
933337 shares
CY2017Q1 us-gaap Securities For Reverse Repurchase Agreements
SecuritiesForReverseRepurchaseAgreements
10000000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82392455
CY2017Q1 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
11914547
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
260683
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1736438
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2238121 shares
CY2017Q1 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
964088
CY2017Q1 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
178361
CY2017Q1 aldx Fair Value Of Warrant Issued
FairValueOfWarrantIssued
266000
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1100000 shares
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.00
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.50
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
211528 shares
CY2015Q1 us-gaap Share Price
SharePrice
20.00
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.33
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14648866
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
983449
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
24517796
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12576325 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12576325 shares
CY2016Q4 us-gaap Assets
Assets
25187679
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25131327
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98938446
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
12897584
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12015061
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
12576
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
275441
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
129
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946251
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1238624
CY2016Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
77546
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Liabilities
Liabilities
3537862
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25187679
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2299238
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2185696
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56352
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
21649817
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77301334
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
218682
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1498585 shares
CY2016Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
913838
CY2016Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
48964
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10600000
CY2017Q1 us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2017-02-17
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1100000 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7100000
CY2015Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
0.125
CY2015Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
211528 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1900000
CY2015Q1 aldx Redemption Price Of Warrants
RedemptionPriceOfWarrants
0.001
CY2015Q1 aldx Expiration Of Warrant
ExpirationOfWarrant
P3Y
CY2015Q1 aldx Average Trading Volume Of Common Stock
AverageTradingVolumeOfCommonStock
50000 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M10D
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-79775
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5196
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3786631 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7287789
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
858096
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1726878
CY2017Q1 us-gaap Depreciation
Depreciation
9660
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5095997
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4780
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4876
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
31617
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-425929
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5091121
CY2017Q1 us-gaap Interest Expense
InterestExpense
26837
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
891541
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
419481
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
42001
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4876
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5095901
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3151867
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10583091
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and <font style="white-space:nowrap">pro-inflammatory</font> chemical species known as aldehydes.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company&#x2019;s principal activities to date include raising capital and research and development activities.</p> </div>
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4186843
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11592
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10583091
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates and assumptions.</p> </div>
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M13D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.12
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M13D
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017Q1 dei Trading Symbol
TradingSymbol
ALDX
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3369023
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
739536 shares
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4055000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
858096
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13797312 shares
CY2017Q1 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2017Q1 aldx Number Of Incentive Plans
NumberOfIncentivePlans
3 Incentive_Plan
CY2017Q1 aldx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
0
CY2017Q1 aldx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
0 shares
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-74656
CY2016Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6978
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3031617 shares
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4500342
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
609108
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1455559
CY2016Q1 us-gaap Depreciation
Depreciation
8102
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4957192
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-316
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-153750
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4967352
CY2016Q1 us-gaap Interest Expense
InterestExpense
25035
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9234
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-273143
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-214043
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
10160
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4967036
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-9750
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10160
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
24719
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4481358
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9234
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3511477
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
609108
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9712521 shares
CY2016Q1 aldx Deferred Offering Costs Paid By Cash
DeferredOfferingCostsPaidByCash
9750

Files In Submission

Name View Source Status
0001193125-17-170649-index-headers.html Edgar Link pending
0001193125-17-170649-index.html Edgar Link pending
0001193125-17-170649.txt Edgar Link pending
0001193125-17-170649-xbrl.zip Edgar Link pending
aldx-20170331.xml Edgar Link completed
aldx-20170331.xsd Edgar Link pending
aldx-20170331_cal.xml Edgar Link unprocessable
aldx-20170331_def.xml Edgar Link unprocessable
aldx-20170331_lab.xml Edgar Link unprocessable
aldx-20170331_pre.xml Edgar Link unprocessable
d361280d10q.htm Edgar Link pending
d361280dex311.htm Edgar Link pending
d361280dex312.htm Edgar Link pending
d361280dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending